Skip to main content

10-05-2017 | Celecoxib | Article

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance)

Edelman MJ et al. J Clin Oncol 2017; 35(19): 2184-2192. doi: 10.1200/JCO.2016.71.3743

Please log in to get access to this content

Related topics